ArticleEClinicalMedicine2024

Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial.

Dimitra Kiritsi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.